| abstract |
This invention provides compounds defined by formula 1 or a pharmaceutically acceptable salt thereof, wherein R1, Q, R2, R3 and R4 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of formula 1, or a pharmaceutically acceptable salt thereof, as defined herein, together with a pharmaceutically acceptable carrier, diluent, or excipient; The invention also provides methods of inhibiting the MMP-13 enzyme in an animal comprising administering to the animal a compound of formula 1, or a pharmaceutically acceptable salt thereof; The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, which comprises administering to the patient a compound of formula 1, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition; The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo and rheumatoid arthritis, heart failure, inflammatory bowel disease, heart failure, age-related macular degeneration, disease chronic obstructive pulmonary, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, which comprises administering to the patient a compound of formula 1, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition; The invention also provides combinations, which comprise a compound of formula 1, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification. |